IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REVOCATION OF POWER OF ATTORNEY AND NEW POWER OF ATTORNEY BY ASSIGNEE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re: the following matters:

Att. Docket No.	Serial No.	Patent No.	Reel / Frame
Epicen-09580	10/719,913		018451/0782
picen-09582	10/719,168		018446/0910
picen-09584	10/719,372		018763/0699
picen-09587	10/743,975		018778/0030
picen-09589	10/744,815		018453/0603
icen-09771	11/093,387		017013/0844
icen-10090	11/235,911		017445/0103
icen-10763	11/352,172		018010/0546
picen-14455	11/787,352		019711/0252

Epicentre Biotechnologies, as Assignee of record of the entire right, title, and interest of each of the above-identified patent applications, or an undivided interest in the entire right, title, and interest of the above-identified patents and patent applications, hereby revokes all previous powers of attorney and appoints:

The practitioners associated with Customer Number 72960

as its attorneys with full power of substitution to prosecute these applications and transact all business in the Patent and Trademark Office in connection therewith.

Please direct all future correspondence and telephone calls regarding this application to:

The address associated with Customer Number 72960

I hereby certify that the Assignment documents filed with each of these applications, or filed subsequent to the filing date of the application, have been reviewed and I hereby certify that, to the best of my knowledge and belief, title is with Epicentre Biotechnologies. A Statement under 37 C.F.R 3.73(b) is included herewith.

Dated: Nov. 14, 2007	By: Jary a. Wall
	Name: GARY A. DAHL
	Title: President and CEO
	Gary A. Dahl, Ph.D. President Epicentre Biotechnologies 726 Post Road Madison. W. 53713

STATEMENT UNDER 37 C.F.R. 3.73(b)

Epicentre Biotechnologies states that it is the assignee of the entire right, title, and interest in the patient applications listed above, or an undivided interest in the entire right, title, and interest in the patients and patient applications listed above, by virtue of assignments by each of the inventor(s) of these patients and patient applications. The assignments were recorded in the United States Patient and Trademark Office at the Reel and Frame Numbers indicated in the right-hand column.

The undersigned (whose title is sup	ipplied below) is authorized to act on behalf of the assign
Dated: Nov. 14, 2007	By. Dary a. Dahl
	Name: GARY A. DAHL
	Title: President and CEO
	Gary A. Dahl, Ph.D. President Epicentre Biotechnologies 729 Post Road Madison, WI 53713
	n

Page 2 of 2